Le Lézard
Classified in: Health, Science and technology

PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops from its Proprietary OPC Platform at ARVO 2024

DAEJEON, South Korea , May 22, 2024 /PRNewswire/ -- PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing next generation therapeutics to treat medical unmet needs, announced that its U.S. subsidiary, Wincal Biopharm, Inc. ("WincalBio"), gained agreat attention at the world's largest ophthalmology conference, Association for Research in Vision and Ophthalmology 2024 (ARVO 2024), when they presented the preclinical data of the eye drop formulation.

WincalBio revealed that currently marketed therapeutic antibodies can be delivered within the eyes using their proprietary Ocular Penetration Carrier (OPC) screening platform, as shown by animal studies. This innovation suggests that non-invasive eye drops could potentially replace traditional intravitreal injection methods for treating eye diseases.

The OPC screening platform was developed to identify antibody-carrier complexes capable of delivering therapeutic agents into the back of the eye, such as the vitreous, retina, and choroid, without relying on needle injections. This allows patients to administer treatment conveniently at home using eye drops. The key to this technology is finding a matching carrier to each antibody to facilitate drug delivery inside the eye.

At ARVO 2024, WincalBio gave an oral presentation  that their OPC screening platform enabled the delivery of the anti-VEGF treatments, Eylea (aflibercept) and Beovu (brolucizumab), as eye drops. In a laser-induced choroid neovascularization (CNV) mouse model, the OPC eye drop formulations demonstrated significant reduction in lesion size and vascular leakage, showing similar efficacy to the intravitreal injections. This breakthrough received huge interest and enthusiasm from the meeting participants.

Dr. Venice Chiueh, Project leader and Director at WincalBio, stated that "Developing eye drop formulations is crucial for enhancing patient convenience and reducing the patient's reluctance to receiving treatment. We are committed to achieving successful outcomes not only in upcoming primate efficacy studies but also in clinical trials."

Dr. TaeWeon Lee, Chief Scientific Officer at WincalBio, added, "These research results are expected to positively impact VC investment opportunities as well as corporate partnerships with biopharma companies with intravitreal therapeutics or planned launch of biosimilars. Our aim is to extend this innovative technology beyond the anti-VEGFantibodies to various eye disease treatments, allowing patients to receive moreconvenient and accessible care."

SOURCE PharmAbcine

These press releases may also interest you

at 22:31
Aetion®, the global leader in real-world evidence (RWE) technology and analytics, announced today the creation of an RWE technology hub in Barcelona, Spain, to convene the most capable group of dedicated RWE technologists in the industry. Aetion also...

at 22:28
On 24 May 2024, Meridian Bidco LLC ("Bidco") made an offer to acquire the entire issued and to be issued share capital of MariaDB plc ("MariaDB") (the...

at 22:00
GenScript, the world-leading biotechnology company specializing in life science research and applications, hosted the inaugural Asia-Pacific (APAC) Distributor Meeting in Nanjing, China. The event, which took place from 3rd to 6th June, brought...

at 21:35
BodyHealth's strawberry flavored PERFECT AMINOtm dietary supplement has been...

at 21:30
Holistic Mental Health Services for All Ages Counseling Unconditionally provides a wide range of therapy services in Louisville including child therapy, teen therapy, couples counseling, and more. Our dedicated therapists use...

at 20:14
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology...

News published on and distributed by: